291 related articles for article (PubMed ID: 24702826)
21. Structural determinants in ApoA-I amyloidogenic variants explain improved cholesterol metabolism despite low HDL levels.
Del Giudice R; Domingo-Espín J; Iacobucci I; Nilsson O; Monti M; Monti DM; Lagerstedt JO
Biochim Biophys Acta Mol Basis Dis; 2017 Dec; 1863(12):3038-3048. PubMed ID: 28887204
[TBL] [Abstract][Full Text] [Related]
22. The polyphenol (-)-epigallocatechin-3-gallate prevents apoA-IIowa amyloidosis in vitro and protects human embryonic kidney 293 cells against amyloid cytotoxicity.
Nakajima H; Nishitsuji K; Kawashima H; Kuwabara K; Mikawa S; Uchimura K; Akaji K; Kashiwada Y; Kobayashi N; Saito H; Sakashita N
Amyloid; 2016; 23(1):17-25. PubMed ID: 26701221
[TBL] [Abstract][Full Text] [Related]
23. Methionine oxidized apolipoprotein A-I at the crossroads of HDL biogenesis and amyloid formation.
Witkowski A; Chan GKL; Boatz JC; Li NJ; Inoue AP; Wong JC; van der Wel PCA; Cavigiolio G
FASEB J; 2018 Jun; 32(6):3149-3165. PubMed ID: 29401604
[TBL] [Abstract][Full Text] [Related]
24. Lipid-free Apolipoprotein A-I Structure: Insights into HDL Formation and Atherosclerosis Development.
Mei X; Atkinson D
Arch Med Res; 2015 Jul; 46(5):351-60. PubMed ID: 26048453
[TBL] [Abstract][Full Text] [Related]
25. The new apolipoprotein A-I variant leu(174) --> Ser causes hereditary cardiac amyloidosis, and the amyloid fibrils are constituted by the 93-residue N-terminal polypeptide.
Obici L; Bellotti V; Mangione P; Stoppini M; Arbustini E; Verga L; Zorzoli I; Anesi E; Zanotti G; Campana C; Viganò M; Merlini G
Am J Pathol; 1999 Sep; 155(3):695-702. PubMed ID: 10487826
[TBL] [Abstract][Full Text] [Related]
26. Evolutionary and structural constraints influencing apolipoprotein A-I amyloid behavior.
Gisonno RA; Masson T; Ramella NA; Barrera EE; Romanowski V; Tricerri MA
Proteins; 2022 Jan; 90(1):258-269. PubMed ID: 34414600
[TBL] [Abstract][Full Text] [Related]
27. Amyloid-Forming Properties of Human Apolipoproteins: Sequence Analyses and Structural Insights.
Das M; Gursky O
Adv Exp Med Biol; 2015; 855():175-211. PubMed ID: 26149931
[TBL] [Abstract][Full Text] [Related]
28. Iowa Mutant Apolipoprotein A-I (ApoA-IIowa) Fibrils Target Lysosomes.
Kameyama H; Nakajima H; Nishitsuji K; Mikawa S; Uchimura K; Kobayashi N; Okuhira K; Saito H; Sakashita N
Sci Rep; 2016 Jul; 6():30391. PubMed ID: 27464946
[TBL] [Abstract][Full Text] [Related]
29. Heparin promotes fibril formation by the N-terminal fragment of amyloidogenic apolipoprotein A-I.
Mikawa S; Mizuguchi C; Nishitsuji K; Baba T; Shigenaga A; Shimanouchi T; Sakashita N; Otaka A; Akaji K; Saito H
FEBS Lett; 2016 Oct; 590(20):3492-3500. PubMed ID: 27654470
[TBL] [Abstract][Full Text] [Related]
30. Effect of Phosphatidylserine and Cholesterol on Membrane-mediated Fibril Formation by the N-terminal Amyloidogenic Fragment of Apolipoprotein A-I.
Mizuguchi C; Nakamura M; Kurimitsu N; Ohgita T; Nishitsuji K; Baba T; Shigenaga A; Shimanouchi T; Okuhira K; Otaka A; Saito H
Sci Rep; 2018 Apr; 8(1):5497. PubMed ID: 29615818
[TBL] [Abstract][Full Text] [Related]
31. Understanding the role of apolipoproteinA-I in atherosclerosis. Post-translational modifications synergize dysfunction?
Ludovico ID; Gisonno RA; Gonzalez MC; Garda HA; Ramella NA; Tricerri MA
Biochim Biophys Acta Gen Subj; 2021 Jan; 1865(1):129732. PubMed ID: 32946930
[TBL] [Abstract][Full Text] [Related]
32. Methionine oxidation induces amyloid fibril formation by full-length apolipoprotein A-I.
Wong YQ; Binger KJ; Howlett GJ; Griffin MD
Proc Natl Acad Sci U S A; 2010 Feb; 107(5):1977-82. PubMed ID: 20133843
[TBL] [Abstract][Full Text] [Related]
33. Phosphatidylethanolamine accelerates aggregation of the amyloidogenic N-terminal fragment of apoA-I.
Kurimitsu N; Mizuguchi C; Fujita K; Taguchi S; Ohgita T; Nishitsuji K; Shimanouchi T; Saito H
FEBS Lett; 2020 May; 594(9):1443-1452. PubMed ID: 31968125
[TBL] [Abstract][Full Text] [Related]
34. Effects of iron on the aggregation propensity of the N-terminal fibrillogenic polypeptide of human apolipoprotein A-I.
Del Giudice R; Pesce A; Cozzolino F; Monti M; Relini A; Piccoli R; Arciello A; Monti DM
Biometals; 2018 Aug; 31(4):551-559. PubMed ID: 29623474
[TBL] [Abstract][Full Text] [Related]
35. Probing the Structure-Function relationship and amyloidogenic propensities in natural variants of apolipoprotein A-I.
Ma'arfi F; Chandra S; Fatima JE; Khan MY; Mir SS; Yusuf MA
Biochem Biophys Rep; 2020 Dec; 24():100815. PubMed ID: 33024841
[TBL] [Abstract][Full Text] [Related]
36. Oxidation of methionine residues in human apolipoprotein A-I generates a potent pro-inflammatory molecule.
Witkowski A; Carta S; Lu R; Yokoyama S; Rubartelli A; Cavigiolio G
J Biol Chem; 2019 Mar; 294(10):3634-3646. PubMed ID: 30635405
[TBL] [Abstract][Full Text] [Related]
37. Apolipoprotein A-1-related amyloidosis 2 case reports and review of the literature.
Lu C; Zuo K; Lu Y; Liang S; Huang X; Zeng C; Zhang J; An Y; Wang J
Medicine (Baltimore); 2017 Sep; 96(39):e8148. PubMed ID: 28953655
[TBL] [Abstract][Full Text] [Related]
38. Proteolysis of apolipoprotein A-I by secretory phospholipase A₂: a new link between inflammation and atherosclerosis.
Cavigiolio G; Jayaraman S
J Biol Chem; 2014 Apr; 289(14):10011-23. PubMed ID: 24523407
[TBL] [Abstract][Full Text] [Related]
39. Structure, function and amyloidogenic propensity of apolipoprotein A-I.
Obici L; Franceschini G; Calabresi L; Giorgetti S; Stoppini M; Merlini G; Bellotti V
Amyloid; 2006 Dec; 13(4):191-205. PubMed ID: 17107880
[TBL] [Abstract][Full Text] [Related]
40. Triglyceride increase in the core of high-density lipoproteins augments apolipoprotein dissociation from the surface: Potential implications for treatment of apolipoprotein deposition diseases.
Jayaraman S; Sánchez-Quesada JL; Gursky O
Biochim Biophys Acta Mol Basis Dis; 2017 Jan; 1863(1):200-210. PubMed ID: 27768903
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
